Oncology Articles & Analysis

Great conversation with Pete Turner and Sandra Ponce de Leon bringing to light how we are discovering novel cancer therapeutics with our innovative ...

By Stelvio Oncology

I'm very excited to be presenting Stelvio Oncology at Indie Bio's Demo Day on September 14, 2017. I'll be on stage presenting with eleven other great biotechnology startup ...

By Stelvio Oncology

We are proud to announce that Stelvio Oncology was successfully accepted into Indie Bio Accelerator, the world's largest seed biotech ...

By Stelvio Oncology

This year, we are going to present TMS for the first time in Europe. Visit our booth #117 at ESMO (European Society for Medical Oncology) 2018 in Munich Germany, in October ...

By Biopticon Corporation

RTsafe launches the Dosimetry Audit Service – succeSRS The complex nature of the stereotactic treatment process demands commitment to the highest levels of accuracy and precision. That being the case we are thrilled to announce the launch of our new dosimetry audit service aiming to promote a culture of excellence. succeSRS is a powerful tool for quality improvement in intracranial ...

By RTsafe

Redbiotec recently hired three additional scientists supporting Redbiotec’s fast growing oncology program. We are happy to observe a big and growing interest in Redbiotec’s COMOS and in Redbiotec’s engineered bacteria. As a consequence Redbiotec will invest further resources in these promising immuno-oncology platforms. Redbiotec is currently also evaluating additional people ...

By Redbiotec AG

In 2019, medPhoton attended the North American Spine Society (NASS) and American Society for Radiation Oncology (ASTRO) conferences in Chicago, USA. At ASTRO, the world’s most important event for radiation oncology, medPhoton once again demonstrated products, image guidance solutions for use cases in particle therapy. Shortly afterwards, Brainlab hosted an exclusive by invitation-only ...

By medPhoton GmbH

Our president Séverine SIGRIST will be present at the 7th edition of the Meet2Win Convention organised by MATWIN, a national programme dedicated to the acceleration of innovative projects in oncology, from 12 to 13 May 2022 in Bordeaux (France). This convention is a chance to learn about oncology and discover the latest innovations, projects and technologies in the field. This year’s ...

By Defymed

NeoTherma Oncology (NTO) announces they have expanded their leadership team with key senior staff who will advance the development and commercialization of the VectRx System. NTO’s new additions include: Ken Belt, Chief Engineer: Ken will lead RF design, and has 48 years of experience in the medical device field with extensive experience in MRI coil and phased array engineering. ...

By NeoTherma Oncology

Neotherma Oncology (NTO) announces the appointment of Bob Larson as Chief Executive Officer effective immediately. Bob is an experienced health care executive with 30+ years spread across the medical device, bio-pharmaceutical, and tech industries. He has held senior leadership positions at companies ranging from startups to Fortune 500 multi-nationals such as Johnson & Johnson and ...

By NeoTherma Oncology

Hyderabad, India, 17th January 2019: Aurobindo Pharma Limited (BSE: 524804 and NSE: AUROPHARMA) ("Aurobindo"), announces the signing of a definitive agreement to acquire a portfolio of seven branded oncology injectable products from Spectrum pharmaceuticals Inc. The acquisition also brings-in an experienced branded commercial infrastructure in the US. Acrotech Biopharma LLC ...

By Aurobindo Pharma Limited

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the upcoming H.C. Wainwright Global Investment Conference, May 23 ...

By Celyad Oncology

Cancer Therapy Advisor (CTA), a leading source of cancer research news and drug information, has been named one of the top breast cancer apps of 2020 by Healthline for the fifth year in a row. The CTA app is designed for oncology professionals and compiles oncology research news, practical cancer treatment regimens, feature articles and expert interviews, slideshows, case studies, and drug ...

By Haymarket Media Group

Françoise Cailler, CEO and Scientific Director of SurgiMab will attend this exciting congress, where world-renowned specialists will gather together during two days to discuss the latest advances in the field of Fluorescence-Guided Surgery. Sessions will cover basic concepts, the use of NIR technology for oncology, colorectal surgery and many more exciting and innovative fields. Click ...

By SurgiMab

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th. A webcast of the fireside chat with AVEO’s management team and H.C. Wainwright research ...

By AVEO Pharmaceuticals, Inc.

It is our great pleasure to announce that Dr. John Chant has accepted our offer as Chief Executive Officer. John will assume the position on Dec 20, 2020. The Board and the founder team are unanimously supportive and excited to have an industry guru with established track record to take the helm. As Filtricine’s current Strategic Advisor, John has been deeply involved in ...

By Filtricine, Inc.

Tethis S.p.A announced today that in the first meeting of the reconfirmed Scientific Advisory Board held today, Nicola Aceto PhD, Professor of Molecular Oncology at the Swiss Federal Institute of Technology (ETH) Zurich, has been appointed as its new chairman. Prof. Aceto is a world-renowned leader in circulating tumor cell research, and his work on CTC clusters has been published in the highest ...

By Tethis S.p.A

Ocala Oncology/Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice. The collaboration will leverage Deep Lens’ artificial intelligence-based clinical trial matching solution, VIPERTM, and other support services to identify the ...

By Deep Lens Inc.

This year, the specialized magazine has selected 22 people, including Rocío Arroyo, who stand out for their talent, leadership, productivity, and power to change the world. Rocío Arroyo has been distinguished by her professional career as scientific, researcher and entrepreneur in the oncologic field with the development of early cancer detection tests by Amadix. Read the ...

By Amadix

Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. Many patients with mCRPC live with reduced physical functioning as ...

By Advanced Accelerator Applications SA